Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.
 

Search Results for “dupilumab”

Dupilumab efficacy and safety in pediatric patients with AD >6 and <18 years

Read More


Study to Assess the Efficacy and Long-term Safety of Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Phase 3 Trial Sponsor Regeneron Pharmaceuticals Collaborator Sanofi Information Provided by Regeneron Pharmaceuticals Purpose The purpose is to demonstrate efficacy and long-term safety of dupilumab in combination with topical corticosteroids in patients with moderate to severe AD. Eligibility Ages Eligible for Study: 18 years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: No […]

Read More


Study of Dupilumab and Immune Responses in Adults with Atopic Dermatitis (AD)

Phase 2 Trial Sponsor Regeneron Pharmaceuticals Collaborator Sanofi Information Provided by Regeneron Pharmaceuticals Purpose This is a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab. Criteria Key Inclusion Criteria Male or female adults ages 18 to 64 years […]

Read More


A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Investigating the Efficacy, Safety, Serum Concentration, and Biomarker Profile of Dupilumab Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Investigating the Efficacy, Safety, Serum Concentration, and Biomarker Profile of Dupilumab Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis

Read More


First Biologic Approved for Moderate to Severe Atopic Dermatitis

The U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD).

Read More


Biologic Therapy

Biologic drugs, or biologics, are among the most targeted therapies available today because they essentially use human DNA to treat certain diseases at the immune system level. Taken subcutaneously (through the skin) or intravenously (in the vein), biologics are genetically engineered medications that contain proteins derived from living tissues or cells cultured in a laboratory. […]

Read More


American Academy of Dermatology 2017 Annual Meeting Wrap-Up

Each year, thousands of doctors, scientists, students, industry and patient advocacy groups like National Eczema Association, gather to hear the latest research and standards of medical care in dermatology at the American Academy of Dermatology (AAD) Annual Meeting. Atopic dermatitis is a hot field of study. Here’s some highlights from this year’s AAD meeting. Biologic […]

Read More


Hope with new AD drugs but will they be covered?

February 21, 2017 — There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to […]

Read More


Understanding Biologic Drugs

January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]

Read More


Shining a Light on the Seriousness of Atopic Dermatitis and New Treatment Options

January 17, 2017 — For the first time, ever, the Institute for Clinical and Economic Review (ICER) has begun a process to review the clinical effectiveness and value of two new treatments for atopic dermatitis (AD). ICER is an independent, nonprofit organization that evaluates treatments for serious diseases such as cancer, multiple sclerosis and psoriasis, […]

Read More